[go: up one dir, main page]

WO2009022216A3 - Rna sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles - Google Patents

Rna sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles Download PDF

Info

Publication number
WO2009022216A3
WO2009022216A3 PCT/IB2008/002104 IB2008002104W WO2009022216A3 WO 2009022216 A3 WO2009022216 A3 WO 2009022216A3 IB 2008002104 W IB2008002104 W IB 2008002104W WO 2009022216 A3 WO2009022216 A3 WO 2009022216A3
Authority
WO
WIPO (PCT)
Prior art keywords
context
rna sequence
specific immune
internucleotide linkages
sequence motifs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2008/002104
Other languages
French (fr)
Other versions
WO2009022216A2 (en
WO2009022216A9 (en
Inventor
Marion Jurk
Jorg Heinz Vollmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Coley Pharmaceutical GmbH
Original Assignee
Coley Pharmaceutical GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40351228&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2009022216(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to EP08789054.7A priority Critical patent/EP2179039B1/en
Priority to AU2008288241A priority patent/AU2008288241B2/en
Priority to NZ582972A priority patent/NZ582972A/en
Priority to JP2010520640A priority patent/JP4847609B2/en
Priority to HK10110254.8A priority patent/HK1143741B/en
Priority to US12/670,697 priority patent/US8128944B2/en
Priority to MX2010001014A priority patent/MX2010001014A/en
Priority to CA2696630A priority patent/CA2696630C/en
Priority to PL08789054T priority patent/PL2179039T3/en
Priority to DK08789054.7T priority patent/DK2179039T3/en
Priority to CN2008801113989A priority patent/CN101821392B/en
Priority to BRPI0814260A priority patent/BRPI0814260B8/en
Application filed by Coley Pharmaceutical GmbH filed Critical Coley Pharmaceutical GmbH
Priority to ES08789054T priority patent/ES2703876T3/en
Priority to SI200832023T priority patent/SI2179039T1/en
Publication of WO2009022216A2 publication Critical patent/WO2009022216A2/en
Publication of WO2009022216A9 publication Critical patent/WO2009022216A9/en
Publication of WO2009022216A3 publication Critical patent/WO2009022216A3/en
Anticipated expiration legal-status Critical
Priority to US13/360,894 priority patent/US8227447B2/en
Priority to US13/494,216 priority patent/US8466124B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)

Abstract

Immunostimulatory polymers that contain certain sequence-dependent immunostimulatory RNA motifs and methods for the use of such immunostimulatory polymers and compositions containing such polymers are provided according to the invention. The sequence-dependent immunostimulatory RNA motifs and the polymers incorporating such motifs are potent and selective inducers of TLR7 and the TLR7- associated cytokine IFN-α.
PCT/IB2008/002104 2007-08-13 2008-08-08 Rna sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles Ceased WO2009022216A2 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
SI200832023T SI2179039T1 (en) 2007-08-13 2008-08-08 Rna sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles
CN2008801113989A CN101821392B (en) 2007-08-13 2008-08-08 RNA sequence motifs that induce specific immunomodulatory properties in the context of defined internucleotide linkages
NZ582972A NZ582972A (en) 2007-08-13 2008-08-08 Rna sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles
JP2010520640A JP4847609B2 (en) 2007-08-13 2008-08-08 RNA sequence motifs in the context of defined internucleotide linkages that elicit specific immune modification profiles
HK10110254.8A HK1143741B (en) 2007-08-13 2008-08-08 Rna sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles
US12/670,697 US8128944B2 (en) 2007-08-13 2008-08-08 RNA sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles
MX2010001014A MX2010001014A (en) 2007-08-13 2008-08-08 Rna sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles.
CA2696630A CA2696630C (en) 2007-08-13 2008-08-08 Rna sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles
PL08789054T PL2179039T3 (en) 2007-08-13 2008-08-08 Rna sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles
EP08789054.7A EP2179039B1 (en) 2007-08-13 2008-08-08 Rna sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles
BRPI0814260A BRPI0814260B8 (en) 2007-08-13 2008-08-08 composition comprising a single-stranded polymer, method comprising contacting a cell with such polymer and using such polymer
AU2008288241A AU2008288241B2 (en) 2007-08-13 2008-08-08 RNA sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles
DK08789054.7T DK2179039T3 (en) 2007-08-13 2008-08-08 RNA sequence motifs associated with defined internucleotide bonds that induce specific immunomodulatory profiles
ES08789054T ES2703876T3 (en) 2007-08-13 2008-08-08 RNA sequence motifs in the context of defined internucleotide linkages that induce specific immunomodulatory profiles
US13/360,894 US8227447B2 (en) 2007-08-13 2012-01-30 RNA sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles
US13/494,216 US8466124B2 (en) 2007-08-13 2012-06-12 RNA sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96444807P 2007-08-13 2007-08-13
US60/964,448 2007-08-13

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US12/670,697 A-371-Of-International US8128944B2 (en) 2007-08-13 2008-08-08 RNA sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles
US201013360894A Division 2007-08-13 2010-01-30
US13/360,894 Division US8227447B2 (en) 2007-08-13 2012-01-30 RNA sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles

Publications (3)

Publication Number Publication Date
WO2009022216A2 WO2009022216A2 (en) 2009-02-19
WO2009022216A9 WO2009022216A9 (en) 2009-04-30
WO2009022216A3 true WO2009022216A3 (en) 2009-06-04

Family

ID=40351228

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/002104 Ceased WO2009022216A2 (en) 2007-08-13 2008-08-08 Rna sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles

Country Status (22)

Country Link
US (3) US8128944B2 (en)
EP (1) EP2179039B1 (en)
JP (1) JP4847609B2 (en)
KR (1) KR20100045508A (en)
CN (1) CN101821392B (en)
AR (1) AR067928A1 (en)
AU (1) AU2008288241B2 (en)
BR (1) BRPI0814260B8 (en)
CA (1) CA2696630C (en)
CL (1) CL2008002371A1 (en)
CO (1) CO6260153A2 (en)
DK (1) DK2179039T3 (en)
ES (1) ES2703876T3 (en)
MX (1) MX2010001014A (en)
NZ (1) NZ582972A (en)
PL (1) PL2179039T3 (en)
PT (1) PT2179039T (en)
RU (1) RU2435851C2 (en)
SI (1) SI2179039T1 (en)
TR (1) TR201820474T4 (en)
TW (1) TW200916106A (en)
WO (1) WO2009022216A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2435851C2 (en) 2007-08-13 2011-12-10 Коули Фармасьютикал ГмбХ Rna sequence motives in context of certain internucleotide linkages, inducing specific immunomodulating profiles
JP2010536907A (en) * 2007-08-31 2010-12-02 ニューリミューン セラピューティクス エイジー Methods for providing patients with specific immune responses in amyloidosis and protein aggregation disorders
WO2009105641A2 (en) 2008-02-20 2009-08-27 New York University Preventing and treating amyloid-beta deposition by stimulation of innate immunity
US9844592B2 (en) 2011-07-18 2017-12-19 Icahn School Of Medicine At Mount Sinai Bacterial RNAs as vaccine adjuvants
CA2953216C (en) * 2014-06-04 2020-12-22 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
EP3220895B1 (en) 2014-11-21 2022-08-31 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
KR20250048594A (en) * 2017-12-15 2025-04-09 엘랑코 애니멀 헬스 게엄베하 Immunostimulatory oligonucleotides
WO2024030844A1 (en) * 2022-08-01 2024-02-08 University Of Mississippi Choline carboxylic acid based ionic liquids as antimicrobial agents

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004004743A1 (en) * 2002-07-03 2004-01-15 Curevac Gmbh Immunostimulation by chemically modified rna
WO2005097993A2 (en) * 2004-02-19 2005-10-20 Coley Pharmaceutical Group, Inc. Immunostimulatory viral rna oligonucleotides
US20060074040A1 (en) * 2003-07-15 2006-04-06 Hybridon, Inc. Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy
WO2007031322A1 (en) * 2005-09-14 2007-03-22 Gunther Hartmann Compositions comprising immunostimulatory rna oligonucleotides and methods for producing said rna oligonucleotides
WO2007062107A2 (en) * 2005-11-25 2007-05-31 Coley Pharmaceutical Gmbh Immunostimulatory oligoribonucleotides

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817321A (en) * 1992-10-08 1998-10-06 Supratek Pharma, Inc. Biological agent compositions
CA2161684C (en) * 1994-03-07 2010-11-09 Larry R. Wilson Bioactive and/or targeted dendrimer conjugates
BR0008227A (en) * 1999-02-15 2001-10-30 Nippon Shinyaku Co Ltd Short-chain polynucleotides and method for their preparation
RU2288921C2 (en) * 2000-12-19 2006-12-10 Калифорниа Инститьют оф Текнолоджи Inclusion complexes-containing compositions
RU2289410C2 (en) * 2001-04-04 2006-12-20 Корикса Корпорейшн Prophylaxis and treatment of infectious and other diseases by using compounds based on mono- n disaccharides
RU2185818C1 (en) * 2001-07-10 2002-07-27 НИИ "Молекулярной медицины" Московской медицинской академии им. И.М. Сеченова Composition for treatment of pulmonary infection
NZ552377A (en) * 2001-08-17 2008-08-29 Coley Pharm Gmbh Combination motif immune stimulatory oligonucleotides with improved activity
ES2543710T3 (en) * 2002-04-04 2015-08-21 Zoetis Belgium S.A. Immunostimulatory oligonucleotides containing G and U
AU2003236258A1 (en) 2002-04-12 2003-10-27 Aisin Aw Co., Ltd. Power supply management system for vehicle mounted apparatus
AU2003300919A1 (en) * 2002-12-11 2004-06-30 Coley Pharmaceutical Gmbh 5' cpg nucleic acids and methods of use
US20050239733A1 (en) * 2003-10-31 2005-10-27 Coley Pharmaceutical Gmbh Sequence requirements for inhibitory oligonucleotides
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
RU2435851C2 (en) * 2007-08-13 2011-12-10 Коули Фармасьютикал ГмбХ Rna sequence motives in context of certain internucleotide linkages, inducing specific immunomodulating profiles

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004004743A1 (en) * 2002-07-03 2004-01-15 Curevac Gmbh Immunostimulation by chemically modified rna
US20060074040A1 (en) * 2003-07-15 2006-04-06 Hybridon, Inc. Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy
WO2005097993A2 (en) * 2004-02-19 2005-10-20 Coley Pharmaceutical Group, Inc. Immunostimulatory viral rna oligonucleotides
WO2007031322A1 (en) * 2005-09-14 2007-03-22 Gunther Hartmann Compositions comprising immunostimulatory rna oligonucleotides and methods for producing said rna oligonucleotides
WO2007062107A2 (en) * 2005-11-25 2007-05-31 Coley Pharmaceutical Gmbh Immunostimulatory oligoribonucleotides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HELL F ET AL: "Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8", SCIENCE, vol. 303, 5 March 2004 (2004-03-05), pages 1526 - 1529, XP002358689, ISSN: 0036-8075 *
HOFFJAN ET AL: "Toll-like receptors and airway disease", DRUG DISCOVERY TODAY: THERAPEUTIC STRATEGIES, vol. 3, no. 3, 23 November 2006 (2006-11-23), pages 317 - 324, XP005777437, ISSN: 1740-6773 *

Also Published As

Publication number Publication date
NZ582972A (en) 2011-09-30
US20120121648A1 (en) 2012-05-17
CL2008002371A1 (en) 2009-07-03
JP4847609B2 (en) 2011-12-28
BRPI0814260B1 (en) 2019-11-12
PT2179039T (en) 2019-01-11
TW200916106A (en) 2009-04-16
BRPI0814260B8 (en) 2021-05-25
AR067928A1 (en) 2009-10-28
AU2008288241A1 (en) 2009-02-19
PL2179039T3 (en) 2019-03-29
WO2009022216A2 (en) 2009-02-19
CN101821392A (en) 2010-09-01
KR20100045508A (en) 2010-05-03
TR201820474T4 (en) 2019-01-21
DK2179039T3 (en) 2019-01-07
MX2010001014A (en) 2010-03-01
BRPI0814260A2 (en) 2015-03-31
CA2696630C (en) 2014-04-01
US8466124B2 (en) 2013-06-18
RU2435851C2 (en) 2011-12-10
EP2179039B1 (en) 2018-10-31
US20100272785A1 (en) 2010-10-28
US20120258140A1 (en) 2012-10-11
EP2179039A2 (en) 2010-04-28
AU2008288241B2 (en) 2011-12-01
CN101821392B (en) 2013-04-17
HK1143741A1 (en) 2011-01-14
JP2010536739A (en) 2010-12-02
US8227447B2 (en) 2012-07-24
ES2703876T3 (en) 2019-03-12
CA2696630A1 (en) 2009-02-19
CO6260153A2 (en) 2011-03-22
US8128944B2 (en) 2012-03-06
RU2010104618A (en) 2011-09-20
WO2009022216A9 (en) 2009-04-30
SI2179039T1 (en) 2019-01-31

Similar Documents

Publication Publication Date Title
WO2009022216A3 (en) Rna sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles
EP4164679A4 (en) Enhanced immunogenic dna/rna compositions and methods
GB202411424D0 (en) Compositions and methods for targeted rna delivery
EP4114939A4 (en) Oligonucleotide compositions and methods thereof
IL308746A (en) Circular rna compositions and methods
WO2009014887A3 (en) Stabilized immune modulatory rna (simra) compounds
WO2008039390A3 (en) Compositions and methods for chitosan enhanced immune response
WO2007064857A3 (en) Amphoteric liposome formulation
WO2011005799A3 (en) Rna containing modified nucleotides and use thereof in vaccines
WO2008089034A3 (en) Cytokine inhibitors
WO2007117686A3 (en) Stabilized immune modulatory rna (simra) compounds for tlr7 and tlr8
WO2017062862A8 (en) Oligonucleotide compositions and methods thereof
MY160608A (en) APTAMERS TO ß-NGF AND THEIR USE IN TREATING ß-NGF MEDIATED DISEASES AND DISORDERS
WO2006116458A3 (en) Modified oligoribonucleotide analogs with enhances immunostimulatory activity
WO2007075896A3 (en) Heterocyclic cytokine inhibitors
MY137619A (en) 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2005023761A3 (en) Cytokine inhibitors
TW200507874A (en) Immunostimulatory nucleic acid oil-in-water formulations and related methods of use
WO2011140595A3 (en) Immunostimulatory and vaccine compositions
WO2007064945A3 (en) Cancer therapies and pharmaceutical compositions used therein
WO2007120673A3 (en) Immunogenic wt-1 peptides and methods of use thereof
WO2005118824A8 (en) Methods and compositions for the inhibition of gene expression
MX2022014161A (en) Sars-cov-2 vaccines.
WO2006071983A3 (en) Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
WO2004005476A3 (en) Nucleic acid compositions for stimulating immune responses

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880111398.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08789054

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12670697

Country of ref document: US

Ref document number: MX/A/2010/001014

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 582972

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 883/DELNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008288241

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2696630

Country of ref document: CA

Ref document number: 2010520640

Country of ref document: JP

Ref document number: 12010500351

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 10016821

Country of ref document: CO

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008789054

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008288241

Country of ref document: AU

Date of ref document: 20080808

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20107005451

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201001491

Country of ref document: UA

WWE Wipo information: entry into national phase

Ref document number: 2010104618

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0814260

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100211